Title: Abiraterone in metastatic prostate cancer without previous chemotherapy
Authors: Ryan, Charles J ×
Smith, Matthew R
de Bono, Johann S
Molina, Arturo
Logothetis, Christopher J
de Souza, Paul
Fizazi, Karim
Mainwaring, Paul
Piulats, Josep M
Ng, Siobhan
Carles, Joan
Mulders, Peter F A
Basch, Ethan
Small, Eric J
Saad, Fred
Schrijvers, Dirk
Van Poppel, Hendrik
Mukherjee, Som D
Suttmann, Henrik
Gerritsen, Winald R
Flaig, Thomas W
George, Daniel J
Yu, Evan Y
Efstathiou, Eleni
Pantuck, Allan
Winquist, Eric
Higano, Celestia S
Taplin, Mary-Ellen
Park, Youn
Kheoh, Thian
Griffin, Thomas
Scher, Howard I
Rathkopf, Dana E
COU-AA-302 Investigators #
Issue Date: Jan-2013
Series Title: New England Journal of Medicine vol:368 issue:2 pages:138-48
Article number: 10.1056/NEJMoa1209096
Abstract: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Organ Systems (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science